MYELODYSPLASTIC SYNDROME
Roche and AbbVie Announce Phase 3 Venclexta Trial Fails to Meet Primary Endpoint in High-Risk MDS
Roche; AbbVie; Venclexta; venetoclax; azacitidine; myelodysplastic syndromes; MDS; Phase 3 trial; VERONA study; clinical trial results; cancer drug
Gilead’s Magrolimab Ineffective, Linked to Increased Risk of Death in MDS Patients
Gilead, Magrolimab, MDS, Myelodysplastic Syndrome, Cancer Treatment, Clinical Trials, Safety Concerns
Geron’s Rytelo Receives FDA Approval for Lower-Risk Myelodysplastic Syndromes Treatment
Geron, Rytelo, FDA Approval, Blood Cancer, Myelodysplastic Syndromes, Telomerase Inhibitor, Imetelstat